Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing

Simple item page
dc.contributor.authorCaudle, Kelly E.
dc.contributor.authorRettie, Allan E.
dc.contributor.authorWhirl-Carrillo, Michelle
dc.contributor.authorSmith, Lisa H.
dc.contributor.authorMintzer, Scott E.
dc.contributor.authorLee, Ming Ta Michael
dc.contributor.authorKlein, Teri E.
dc.contributor.authorCallaghan, J. Thomas
dc.contributor.departmentDepartment of Neurology, IU School of Medicineen_US
dc.date.accessioned2016-02-26T16:27:20Z
dc.date.available2016-02-26T16:27:20Z
dc.date.issued2014-11
dc.description.abstractPhenytoin is a widely used antiepileptic drug with a narrow therapeutic index and large inter-patient variability partly due to genetic variations in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotype (also available on PharmGKB: www.pharmgkb.org).en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationCaudle, K. E., Rettie, A. E., Whirl-Carrillo, M., Smith, L. H., Mintzer, S. E., Lee, M. T. M., … Callaghan, J. T. (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing. Clinical Pharmacology and Therapeutics, 96(5), 542–548. http://doi.org/10.1038/clpt.2014.159en_US
dc.identifier.issn0009-9236en_US
dc.identifier.urihttps://hdl.handle.net/1805/8529
dc.language.isoen_USen_US
dc.publisherNature Publishing Groupen_US
dc.relation.isversionof10.1038/clpt.2014.159en_US
dc.relation.journalClinical pharmacology and therapeuticsen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectAnticonvulsantsen_US
dc.subjectadministration & dosageen_US
dc.subjectCytochrome P-450 CYP2C9en_US
dc.subjectGeneticsen_US
dc.subjectHLA-B Antigensen_US
dc.subjectPhenytoinen_US
dc.titleClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosingen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nihms622159.pdf
Size:
291.3 KB
Format:
Adobe Portable Document Format
Description:
Author's manuscript
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Neurology Works